ITMCTR2024000180
Not yet recruiting
Early Phase 1
Characteristics of biomarker on dermal sensitization for myocardial ischemia-reperfusion injury
the Affiliated Hospital of Shaanxi University of Chinese Medicine0 sitesTBD
Conditionsmyocardial ischemia reperfusion injury
Overview
- Phase
- Early Phase 1
- Intervention
- Not specified
- Conditions
- myocardial ischemia reperfusion injury
- Sponsor
- the Affiliated Hospital of Shaanxi University of Chinese Medicine
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •MIRI patients:
- •(1\) meeting the diagnostic criteria of non\-ST elevation acute coronary syndrome in 2023 ESC Guidelines for the management of acute coronary syndromes.
- •(2\) received percutaneous coronary intervention within a week.
- •(3\) aged 18 to 85 years.
- •(4\) willing to participate in this study, and sign on informed consent.
- •Healthy subjects:
- •(1\) received a health examination within a week, and confirmed to be in good health.
- •(2\) aged 18 to 85 years, and matching the MIRI patients.
- •(3\) willing to participate in this study, and sign on informed consent.
Exclusion Criteria
- •(1\) diagnosed as ST\-elevation myocardial infarction, with persistent ST\-segment elevation or ST\-segment elevation equivalents on electrocardiogram.
- •(2\) combined with disorders of rhythm, disorders of the heart, muscles, valves, and pericardium, and peripheral vascular disease.
- •(3\) suffering from neoplastic disorders, hematopoietic disorders, disorders of hemostasis, infectious diseases, immune\-mediated, inflammatory, and rheumatologic disorders.
- •(4\) combined with fever.
- •(5\) suffering from psychiatric disorders, and unable to cooperate.
- •(6\) participating in any other study using an unapproved drug within 3 months.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
AMBITIOUSAtopic Dermatitis Biomarker Identification Trial in Omalizumab UsageSingle- arm trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitis - AMBITIOUSAMBITIOUS is a trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitisAtopische Dermatitis is a common inflammatory skin disease showing chronically relapsing eczema and high association with elevated serum IgE levels.MedDRA version: 14.0Level: LLTClassification code 10029264Term: Neurodermatitis aggravatedSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-018559-84-DEMedizinische Fakultät der technischen Universität Muenchen20
Not yet recruiting
Not Applicable
Safety assessment of products on skiCTRI/2021/02/031141Alaina Healthcare Pvt Ltd
Not yet recruiting
Not Applicable
Safety assessment of productsCTRI/2021/02/031594Kama Ayurveda Pvt Ltd
Completed
Not Applicable
To study the irritant and allergic potential of test products in Men and Women.CTRI/2023/10/058731Dabur Research and Development Centre209
Not yet recruiting
Early Phase 1
Biological characteristics of sensitization characterization in patients with chronic colitisITMCTR2024000126shaaxi University of Traditional Chinese Medicine